> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Xencor's $39.4 Million Quarterly Profit Leans On A $105.0 Million Alexion Settlement Paid Half In Cash
- URL: https://www.bullished.co/xencors-39-4-million-quarterly-profit-leans-on-a-105-0-million-alexion-settlement-paid-e53d7c11/
- Published: 2026-11-04T21:08:19.000Z
- Updated: 2026-11-04T21:08:19.000Z
- Description: Alexion has paid $52.5 million of the settlement, so receivables jumped to $64.8 million and nine-month operating cash flow was negative $120.6 million.
- Author: Matteo Parrino
- Tags: SEC Filings, XNCR, Industry: Healthcare

[Xencor](https://www.bullished.co/tag/xncr/), a clinical-stage biotech that designs engineered XmAb antibodies for cancer and autoimmune disease, [booked $116.5 million of third-quarter revenue](https://www.sec.gov/Archives/edgar/data/0001326732/000132673226000063/xncr-20260930.htm?ref=bullished.co), and $77.4 million of it is the leftover slice of a $105.0 million royalty settlement with Alexion. Only half of the settlement has arrived in cash, which is why a $39.4 million quarterly net profit sits beside a nine-month net loss of $111.2 million.

## Half the settlement is still owed

Xencor and Alexion settled on July 29 a dispute over U.S. royalties on Ultomiris. Alexion pays $105.0 million in two equal installments of $52.5 million. The first arrived in August, and the second is due within 14 days after the settlement's one-year anniversary.

Xencor booked $27.6 million of the total as second-quarter revenue and the remaining $77.4 million in the third quarter, as royalties for periods after June 30\. The [prior 10-Q](https://www.sec.gov/Archives/edgar/data/0001326732/000132673226000056/xncr-20260630.htm?ref=bullished.co) had said the settlement resolved the uncertainty over that revenue. Alexion has no further U.S. Ultomiris royalty obligation once it has paid in full, and its ex-U.S. royalties are unaffected.

The dispute began March 4, when Alexion said it owed no more U.S. royalties. Xencor constrained that revenue to zero and recorded a $6.6 million reduction in the first quarter.

## Profit quarter, loss year

Revenue was $116.5 million against $21.0 million a year earlier. Operating income was $22.9 million for the quarter, but the nine-month operating loss was $92.1 million.

Accounts receivable rose to $64.8 million from $29.3 million at year-end; the Alexion piece was $61.0 million, of which $8.5 million will be paid directly to OMERS, the buyer of some Ultomiris royalties. Cash used in operations was $120.6 million for the nine months, and the company said the receivable build tied to the settlement was a main driver.

Research spending climbed to $84.3 million from $54.4 million a year earlier. General and administrative expense fell to $9.4 million, helped by a non-recurring legal-expense recovery that includes a $7.0 million payment from Merus, which settled its patent dispute with Xencor in July.

Cash and marketable debt securities were $555.7 million, down from $610.8 million at year-end. Xencor's runway language now reads into 2029, and it expects to end 2026 with $480 million to $500 million.

## Pipeline and royalty obligations

Xencor picked a 400 mcg/kg intravenous dose of XmAb819, its kidney-cancer T-cell engager, for Phase 3\. Five of 11 evaluable patients had confirmed partial responses, a 45.5% confirmed response rate. It plans to talk to the FDA in the first half of 2027 about a possible accelerated approval path.

The liability for royalties sold to OMERS fell to $95.1 million from $119.7 million at year-end. The Ultomiris effective interest rate was 17.0%. Xencor is obligated to cover some OMERS royalty shortfalls, and $5.0 million of its cash is restricted for that purpose.

The second $52.5 million installment is due within 14 days after the settlement's one-year anniversary, and Xencor's release puts it in the third quarter of 2027.

### Sources

- [10-Q Filing — Xencor (XNCR)](https://www.sec.gov/Archives/edgar/data/0001326732/000132673226000063/xncr-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Xencor (XNCR), Q2 FY2026 filed 2026-08-05 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001326732/000132673226000056/xncr-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, xncr-20261104xexx991.htm) — Xencor, filed 2026-11-04](https://www.sec.gov/Archives/edgar/data/0001326732/000132673226000062/xncr-20261104xexx991.htm?ref=bullished.co) — SEC EDGAR

### More on Xencor

- [Xencor Picks Top Dose For Kidney Cancer Drug After 45.5% Response Rate In Small Cohort](https://www.bullished.co/xencor-picks-top-dose-for-kidney-cancer-drug-after-45-5-response-rate-in-small-cohort-28a12fc5/)

[All Xencor (XNCR) coverage →](https://www.bullished.co/tag/xncr/)